Genotype-specific MRD interpretation improves stratification in paediatric acute lymphoblastic leukaemia

Genotype-specific MRD interpretation improves stratification in paediatric acute lymphoblastic leukaemia

<strong>Purpose</strong> Minimal residual disease (MRD) and genetic abnormalities are important risk factors for outcome in acute lymphoblastic leukemia. Current risk algorithms dichotomize MRD data and do not assimilate genetics when assigning MRD risk, which reduces predictive accuracy...

Description complète

Détails bibliographiques
Auteurs principaux:	O'Connor, D, Enshaei, A, Bartram, J, Hancock, J, Harrison, C, Hough, R, Samarasinghe, S, Schwab, C, Vora, A, Wade, R, Moppett, J, Moorman, A, Goulden, N
Format:	Journal article
Publié:	American Society of Clinical Oncology 2017

Documents similaires

Cytogenetic-specific heterogeneity in the kinetics of minimal residual disease (MRD) clearance in childhood acute lymphoblastic leukaemia (ALL)
par: Moorman, A, et autres
Publié: (2007)

Use of Minimal Residual Disease Assessment to Redefine Induction Failure in Pediatric Acute Lymphoblastic Leukemia.
par: O'Connor, D, et autres
Publié: (2017)

A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia.
par: Moorman, A, et autres
Publié: (2014)

Post-Remission MRD Kinetics in Children with Acute Lymphoblastic Leukaemia Receiving Augmented BFM Consolidation Compared with Other Regimens Results of the Medical Research Council Trial UKALL2003.
par: Cutting, R, et autres
Publié: (2008)

Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol.
par: Patrick, K, et autres
Publié: (2014)

Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol
par: Patrick, K, et autres
Publié: (2014)

Delineation of Risk Factors in Paediatric Acute Lymphoblastic Leukaemia with Favourable Cytogenetics
par: Moorman, A, et autres
Publié: (2012)

Post-remission MRD kinetics in children with acute lymphoblastic leukaemia receiving augmented BFM consolidation compared with other regimens: update of results of the Medical Research Council Trial UKALL2003
par: Cutting, R, et autres
Publié: (2009)

Cytogenetic-specific heterogeneity in the kinetics of minimal residual disease (MIRD) clearance in childhood lymphoblastic leukaemia (ALL)
par: Moorman, A, et autres
Publié: (2008)

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
par: Vora, A, et autres
Publié: (2014)

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): A randomised controlled trial
par: Vora, A, et autres
Publié: (2014)

Down Syndrome is a significant risk factor for infectious deaths in childhood acute lymphoblastic leukaemia: a retrospective analysis of the infectious deaths on UKALL 2003
par: O'Connor, D, et autres
Publié: (2014)

Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003
par: Patrick, K, et autres
Publié: (2014)

Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003.
par: Patrick, K, et autres
Publié: (2014)

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
par: Vora, A, et autres
Publié: (2013)

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial
par: Vora, A, et autres
Publié: (2013)

Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003
par: Samarasinghe, S, et autres
Publié: (2013)

Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003.
par: Samarasinghe, S, et autres
Publié: (2013)

PCR-based MRD testing for acute lymphoblastic leukaemia in India
par: Rubina Islam, et autres
Publié: (2017-01-01)

Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003.
par: O'Connor, D, et autres
Publié: (2014)

Comparison of clinical significance of MRD as determined by IgH genescanning or allele specific probing in childhood ALL.
par: Moppett, J, et autres
Publié: (2002)

Profile of Steroid Toxicity During Maintenance Treatment in Teenage and Young Adult (TYA) Patients with Acute Lymphoblastic Leukaemia (ALL)
par: Tomlins, J, et autres
Publié: (2012)

Improved Outcome for Children and Young Adults with T-Cell Acute Lymphoblastic Leukaemia (ALL): Results of the United Kingdom Medical Research Council (MRC) Trial UKALL 2003
par: Vora, A, et autres
Publié: (2008)

Efficacy and Toxicity of Pegylated Asparaginase in the Treatment of Children and Young Adults with Acute Lymphoblastic Leukaemia: Results of the United Kingdom Medical Research Council (MRC) Trial UKALL 2003
par: Vora, A, et autres
Publié: (2008)

Incidence and Outcome of Osteonecrosis in Children and Young Adults with Acute Lymphoblastic Leukaemia Treated on a Dexamethasone Containing Protocol: Results of the Medical Research Council UK Trial ALL 2003
par: Vora, A, et autres
Publié: (2008)

Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: a comparison of the MRC ALL97/99 and UKALL2003 trials.
par: Moorman, A, et autres
Publié: (2013)

The impact of risk stratification by early bone-marrow response in childhood lymphoblastic leukaemia: results from the United Kingdom Medical Research Council trial ALL97 and ALL97/99.
par: Mitchell, C, et autres
Publié: (2009)

Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials.
par: Ramanujachar, R, et autres
Publié: (2007)

Late relapsing childhood lymphoblastic leukaemia.
par: Frost, L, et autres
Publié: (1997)

UKALL 2003, A Randomised Trial Investigating Treatment Reduction for Children and Young Adults with Minimal Residual Disease Defined Low Risk Acute Lymphoblastic Leukaemia
par: Vora, A, et autres
Publié: (2010)

UKALL 2003, A Randomised Trial Investigating Treatment Reduction for Children and Young Adults with Minimal Residual Disease Defined Low Risk Acute Lymphoblastic Leukaemia
par: Vora, A, et autres
Publié: (2010)

UKALL 2003, A Randomised Trial Investigating Treatment Reduction for Children and Young Adults with Minimal Residual Disease Defined Low Risk Acute Lymphoblastic Leukaemia
par: Vora, A, et autres
Publié: (2010)

PROSPECTIVE EVALUATION OF QUALITY OF LIFE (QOL) IN CHILDREN TREATED IN UKALL 2003 FOR ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL): A COHORT STUDY
par: Eiser, C, et autres
Publié: (2012)

Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia.
par: Harrison, C, et autres
Publié: (2004)

Late relapsing childhood acute lymphoblastic leukaemia.
par: Frost, L, et autres
Publié: (1998)

Intraocular relapse of childhood acute lymphoblastic leukaemia.
par: Somervaille, T, et autres
Publié: (2003)

Variables affecting kinetics of minimal residual disease clearance in children with lymphoblastic leukaemia; Results of the United Kingdom Medical Research Council (UK MRC) protocols ALL97, ALL97/99 and ALL2003.
par: Vora, A, et autres
Publié: (2005)

Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia.
par: Lennard, L, et autres
Publié: (2013)

Treatment of infants with lymphoblastic leukaemia: results of the UK Infant Protocols 1987-1999.
par: Chessells, J, et autres
Publié: (2002)

Molecular mechanisms involved in chemoresistance in paediatric acute lymphoblastic leukaemia
par: Stanković Tatjana, et autres
Publié: (2008-01-01)